Year Published
- 2008 (0)
- 2009 (10) Apply 2009 filter
- 2010 (6) Apply 2010 filter
- 2011 (3) Apply 2011 filter
- 2012 (0)
- (-) Remove 2013 filter 2013
- 2014 (1) Apply 2014 filter
- 2015 (4) Apply 2015 filter
- 2016 (5) Apply 2016 filter
- (-) Remove 2017 filter 2017
- 2018 (2) Apply 2018 filter
- 2019 (0)
- 2020 (0)
- 2021 (1) Apply 2021 filter
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (2) Apply Smallholder Farmers filter
- Women (1) Apply Women filter
Types of Research
- Data Analysis (4) Apply Data Analysis filter
- (-) Remove Literature Review filter Literature Review
- Portfolio Review (0)
- (-) Remove Research Brief filter Research Brief
Geography
- East Africa Region and Selected Countries (1) Apply East Africa Region and Selected Countries filter
- Global (3) Apply Global filter
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (1) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (1) Apply Farmer First filter
- LSMS & LSMS-ISA (1) Apply LSMS & LSMS-ISA filter
- Other Datasets (0)
Current search
- (-) Remove 2017 filter 2017
- (-) Remove 2013 filter 2013
- (-) Remove Finance & Investment filter Finance & Investment
- (-) Remove Risk, Preferences, & Decision-Making filter Risk, Preferences, & Decision-Making
- (-) Remove Research Brief filter Research Brief
- (-) Remove Technology Adoption filter Technology Adoption
- (-) Remove Literature Review filter Literature Review
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.
A growing body of evidence suggests that empowering women may lead to economic benefits (The World Bank, 2011; Duflo, 2012; Kabeer & Natali, 2013). Little work, however, focuses specifically on the potential impacts of women’s empowerment in agricultural settings. Through a comprehensive review of literature this report considers how prioritizing women’s empowerment in agriculture might lead to economic benefits. With an intentionally narrow focus on economic empowerment, we draw on the Women’s Empowerment in Agriculture Index (WEAI)’s indicators of women’s empowerment in agriculture to consider the potential economic rewards to increasing women’s control over agricultural productive resources (including their own time and labor), over agricultural production decisions, and over agricultural income. While we recognize that there may be quantifiable benefits of improving women’s empowerment in and of itself, we focus on potential longer-term economic benefits of improvements in these empowerment measures.
Consumer attitudes are a key component in private sector market segmentation. Knowledge about consumers’ tastes can lead to better product design and more effective communication with target markets. Similarly, evidence suggests that farmers’ attitudes influence whether they adopt productivity-increasing technologies. Using consumer insights from the private sector, agricultural intervention programs can use market research, product development, and communication strategies to better understand farmers as consumers and best target interventions. This brief provides an overview of how farmers' attitudes affect their willingness to adopt new technology, and how knowledge of farmer attitudes can improve program design and implementation.
This desk study reports on the small-scale machinery sector in China and a selection of SSA countries: Ethiopia, Tanzania, Nigeria, Burkina Faso, and Uganda. The report is organized into three sections. Section 1 discusses the current state of small-scale agricultural machinery in SSA for crop and livestock production in each of the SSA countries identified. It also seeks to identify major areas of need in terms of agricultural mechanization and major constraints to agricultural machinery adoption, dissemination and maintenance. Section 2 focuses on the agricultural machinery sector in China and Chinese Africa relationships in agricultural development. It also identifies the major government players in the Chinese agricultural machinery sector. Section 3 is a “directory” of small-scale agricultural machinery manufactured in China with potential relevance for SSA smallholder farmers. We divide machines by function (e.g. threshing) although many Chinese machines are multi-function and can serve multiple purposes. We also note applicable crops, if listed by the manufacturers, and technical specifications as available.